Provided are pharmaceutical compositions comprising empagliflozin and one or more antiobesity drugs, for use in the treatment of metabolic disorders in overweight or obese patients. Preferred antiobesity drugs include cetilistat, sibutramine, orlistat, a combination of phentermine and topiramate, a combination of naltrexone and bupropion, lorcaserin and liraglutide.